{"id":"W2048627371","doi":"10.1186/bcr3011","title":"Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer","year":2011,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Capecitabine; Sorafenib; Medicine; Internal medicine; Placebo; Oncology; Breast cancer; Surgical oncology; Hazard ratio; HER2 negative; Metastatic breast cancer; Cancer; Confidence interval; Hepatocellular carcinoma; Colorectal cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002122054,0.001902487,0.001957619,0.0006860881,0.0003795541,0.0009273094,0.0008829284,0.001258555,0.007851709],"category_scores_gemma":[0.002288116,0.0006271522,0.002031921,0.0003584612,0.001427058,0.001073178,0.0007861928,0.002765231,0.001335353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006481428,"about_ca_system_score_gemma":0.001697966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00057426,"about_ca_topic_score_gemma":0.001369741,"domain_scores_codex":[0.9991226,0.0004973199,0.00004296893,0.0001270575,0.0000630924,0.000146898],"domain_scores_gemma":[0.9992854,0.0001408092,0.000201548,0.00006136838,0.0000290599,0.0002818625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9598919,0.0117528,0.0006686324,0.0005960953,0.000907973,0.00008864239,0.00008509459,0.0007017951,0.007647766,0.0003672314,0.0008697056,0.01642227],"study_design_scores_gemma":[0.9165977,0.0805131,0.0008934659,0.00002240624,0.000299589,0.00002835985,0.00001625797,0.0001986034,0.0004798551,0.0002375067,0.0006991638,0.00001395534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9723238,0.002575696,0.002015421,0.002096141,0.001022003,0.01474576,0.001386997,0.0003027654,0.003531374],"genre_scores_gemma":[0.9568768,0.002439246,0.005900332,0.002266366,0.0006196889,0.02484027,0.001295596,0.00006396539,0.005697684],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.007851709,"threshold_uncertainty_score":0.02626663,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2128159828587136,"score_gpt":0.4763384902362042,"score_spread":0.2635225073774906,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}